| Assay ID | Title | Year | Journal | Article |
|---|
| AID1222188 | Activity of recombinant human CYP3A4 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated compound depletion at 0.02 uM after 30 mins by LC-MS analysis | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1301651 | Antagonist activity against CysLT2 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of LTD4-induced calcium mobilization pre-incubated for 10 mins before LTD4 addition by Fluo-4 AM dye based fluorimetric assay | 2016 | ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
| Discovery of 3-Substituted 1H-Indole-2-carboxylic Acid Derivatives as a Novel Class of CysLT1 Selective Antagonists. |
| AID1222192 | Activity of recombinant human CYP2A6 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated metabolite formation at 10 uM after 60 mins by LC-MS analysis | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222230 | Drug metabolism in human liver microsomes assessed as 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetic acid formation at 0.02 to 0.4 uM preincubated for 3 mins followed by | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222173 | Activity of recombinant human CYP2C8 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated (R)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(4-hydroxy-2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)c | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222217 | Drug metabolism in human liver microsomes assessed as 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxy-3-(2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetic acid formation at 0.1 uM after 12 mins by LC-MS analysis in pre | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1903426 | Anti-asthmatic activity against ovalbumin-induced asthmatic mouse model assessed as decrease in IL-4 level in BALF at 1.3 mg/kg, po administered once daily for 7 days by ELISA | | | |
| AID1222159 | Activity of recombinant human CYP2C8 expressed in microsomes isolated from baculovirus infected insect cell assessed as intrinsic clearance for enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl) | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222165 | Unbound plasma concentration in human at 10 mg, po | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222167 | Ratio of drug level in blood to plasma in human | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1301652 | Antagonist activity at LTD4 receptor in splenocytes isolated from MOG(35 to 55 residues) containing CFA immunized and pertussis toxin-induced C57BL/6 mouse experimental autoimmune encephalomyelitis model assessed as inhibition of LTD4-induced leukocyte ch | 2016 | ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
| Discovery of 3-Substituted 1H-Indole-2-carboxylic Acid Derivatives as a Novel Class of CysLT1 Selective Antagonists. |
| AID1222187 | Activity of recombinant human CYP2C8 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated compound depletion at 0.02 uM after 30 mins by LC-MS analysis | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222166 | Plasma clearance in human at 3 to 18 mg, iv | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1903424 | Anti-asthmatic activity against ovalbumin-induced asthmatic mouse model assessed as decrease in IgE level in serum at 1.3 mg/kg, po administered once daily for 7 days by ELISA | | | |
| AID1222175 | Activity of recombinant human CYP2C9 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated (R)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(4-hydroxy-2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)c | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222208 | Inhibition of recombinant human CYP2C9 expressed in microsomes isolated from baculovirus infected insect cell after 10 mins | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222172 | Activity of recombinant human CYP2C9 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl)propylthio)methyl)cyclop | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222206 | Inhibition of recombinant human CYP2C8 expressed in microsomes isolated from baculovirus infected insect cell after 3 mins | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222176 | Activity of recombinant human CYP3A5 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated (R)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(4-hydroxy-2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)c | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222158 | Activity of recombinant human CYP2C9 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl)propylthio)methyl)cyclop | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222210 | Drug metabolism in human liver microsomes assessed as 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetic acid formation at 0.4 uM after 15 mins by LC-MS analysis in presence | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222205 | Activity of recombinant human CYP2C8 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl)propylthio)methyl)cyclop | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222209 | Activity of recombinant human CYP2C8 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl)propylthio)methyl)cyclop | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222190 | Activity of recombinant human CYP3A5 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated compound depletion at 0.02 uM after 30 mins by LC-MS analysis | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1903443 | Binding affinity to immobilized Halo tag-fused CysLT receptor (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as dissociation rate constant by receptor chromatography | | | |
| AID1222174 | Activity of recombinant human CYP3A4 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated (R)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(4-hydroxy-2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)c | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222213 | Drug metabolism in human liver microsomes assessed as 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetic acid formation at 0.4 uM after 15 mins by LC-MS analysis in presence | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222171 | Activity of recombinant human CYP2C8 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl)propylthio)methyl)cyclop | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222233 | Drug metabolism in human liver microsomes assessed as 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxy-3-(2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetic acid formation at 0.4 uM after 15 mins by LC-MS analysis in pre | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222169 | Activity of recombinant human CYP3A4 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxy-3-(2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl) | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222185 | Activity of recombinant human CYP2C9 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl)propylthio)methyl)cyclop | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222226 | Drug metabolism in human liver microsomes at 1 to 10 uM preincubated for 3 mins followed by beta-NADPH addition by LC-MS analysis in presence of albumin | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1903434 | Decrease in CysLT receptor expression in bronchus in ovalbumin-induced asthmatic mouse model at 1.3 mg/kg, po administered once daily for 7 days by Western blot analysis | | | |
| AID1222189 | Activity of recombinant human CYP2C9 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated compound depletion at 0.02 uM after 30 mins by LC-MS analysis | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1903444 | Binding affinity to immobilized Halo tag-fused CysLT receptor (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as association rate constant by receptor chromatography | | | |
| AID1222224 | Oral bioavailability in human at 10 mg administered through tablet | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222218 | Drug metabolism in human liver microsomes assessed as 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetic acid formation at 0.1 uM after 12 mins by LC-MS analysis in presence | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1903438 | Binding affinity to immobilized Halo tag-fused CysLT receptor (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as retention time by chromatography | | | |
| AID1222221 | Drug metabolism in human liver microsomes assessed as (R)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(4-hydroxy-2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetic acid formation at 0.1 uM after 12 mins by LC-MS analysis in pres | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222231 | Drug metabolism in human liver microsomes assessed as 2-(2-((R)-3-((1-(carboxymethyl)cyclopropyl)methylthio)-3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)propyl)phenyl)-2-hydroxypropanoic acid formation at 0.02 to 0.4 uM preincubated for 3 mins followed by | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222227 | Drug metabolism in human liver microsomes assessed as 2-(1-(((S)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propylsulfinyl)methyl)cyclopropyl)acetic acid formation at 0.02 to 0.4 uM preincubated for 3 mins followed by b | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222160 | Activity of recombinant human CYP2C9 expressed in microsomes isolated from baculovirus infected insect cell assessed as intrinsic clearance for enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl) | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222220 | Activity of recombinant human CYP2C9 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl)propylthio)methyl)cyclop | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222225 | Drug metabolism in human liver microsomes at 1 to 10 uM preincubated for 3 mins followed by beta-NADPH addition by LC-MS analysis | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222215 | Drug metabolism in human liver microsomes assessed as 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetic acid formation at 0.05 uM after 15 mins by LC-MS analysis in presence | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1903442 | Binding affinity to immobilized Halo tag-fused CysLT receptor (unknown origin) expressed in Escherichia coli BL21 (DE3) by receptor chromatography | | | |
| AID1222170 | Activity of recombinant human CYP3A5 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxy-3-(2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl) | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222162 | Activity of recombinant human CYP3A5 expressed in microsomes isolated from baculovirus infected insect cell assessed as intrinsic clearance for enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl) | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1446800 | Inhibition of cysteinyl leukotriene receptor 1 (unknown origin) expressed in HEK293 cell membranes after 45 mins by scintillation spectrometry | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
| Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery. |
| AID1222228 | Drug metabolism in human liver microsomes assessed as (R)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(4-hydroxy-2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetic acid formation at 0.02 to 0.4 uM preincubated for 3 mins followe | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1903430 | Anti-asthmatic activity against ovalbumin-induced asthmatic mouse model assessed as decrease in IL-13 level in BALF at 1.3 mg/kg, po administered once daily for 7 days by ELISA | | | |
| AID1222212 | Drug metabolism in human liver microsomes assessed as 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxy-3-(2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetic acid formation at 0.4 uM after 15 mins by LC-MS analysis in pre | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1301655 | Antagonist activity at LTD4 receptor in splenocytes isolated from MOG(35 to 55 residues) containing CFA immunized and pertussis toxin-induced C57BL/6 mouse experimental autoimmune encephalomyelitis model assessed as inhibition of LTD4-induced leukocyte ch | 2016 | ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
| Discovery of 3-Substituted 1H-Indole-2-carboxylic Acid Derivatives as a Novel Class of CysLT1 Selective Antagonists. |
| AID1903428 | Anti-asthmatic activity against ovalbumin-induced asthmatic mouse model assessed as decrease in IL-5 level in BALF at 1.3 mg/kg, po administered once daily for 7 days by ELISA | | | |
| AID1222182 | Activity of recombinant human CYP2C8 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl)propylthio)methyl)cyclop | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222163 | Fraction unbound in human plasma | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222177 | Activity of recombinant human CYP2C19 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated (R)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(4-hydroxy-2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl) | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222184 | Activity of recombinant human CYP2C8 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated (R)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(4-hydroxy-2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)c | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222222 | Activity of recombinant human CYP2C8 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated (R)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(4-hydroxy-2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)c | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222191 | Activity of recombinant human CYP2A6 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated compound depletion at 0.02 uM after 30 mins by LC-MS analysis | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222207 | Activity of recombinant human CYP2C9 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl)propylthio)methyl)cyclop | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222223 | Plasma protein binding in human | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222219 | Activity of recombinant human CYP2C8 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl)propylthio)methyl)cyclop | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222164 | Cmax in human at 10 mg, po | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1903420 | Anti-asthmatic activity against ovalbumin-induced asthmatic mouse model assessed as infiltration of inflammatory cells in the perivascular and peribronchiolar region of lungs at 1.3 mg/kg, po administered once daily for 7 days by H and E staining based li | | | |
| AID1222204 | Intrinsic clearance in human liver microsomes assessed as Vmax/Km at 0.02 uM | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222214 | Drug metabolism in human liver microsomes assessed as (R)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(4-hydroxy-2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetic acid formation at 0.4 uM after 15 mins by LC-MS analysis in pres | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222229 | Drug metabolism in human liver microsomes assessed as 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxy-3-(2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetic acid formation at 0.02 to 0.4 uM preincubated for 3 mins follow | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222161 | Activity of recombinant human CYP3A4 expressed in microsomes isolated from baculovirus infected insect cell assessed as intrinsic clearance for enzyme-mediated 2-(1-(((1R)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1,2-dihydroxypropan-2-yl)phenyl) | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1301650 | Antagonist activity against CysLT1 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of LTD4-induced calcium mobilization pre-incubated for 10 mins before LTD4 addition by Fluo-4 AM dye based fluorimetric assay | 2016 | ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
| Discovery of 3-Substituted 1H-Indole-2-carboxylic Acid Derivatives as a Novel Class of CysLT1 Selective Antagonists. |
| AID1222211 | Drug metabolism in human liver microsomes assessed as (R)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(4-hydroxy-2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetic acid formation at 0.4 uM after 15 mins by LC-MS analysis in pres | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1222168 | Activity of recombinant human CYP2C9 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated (R)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(4-hydroxy-2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)c | 2011 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
| Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. |
| AID1347158 | ZIKV-mCherry secondary qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347169 | Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347164 | 384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347167 | Vero cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347161 | Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347152 | Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347156 | DAPI mCherry counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347163 | 384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347153 | Confirmatory screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347168 | HepG2 cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347149 | Furin counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID720501 | qHTS for Inhibitors of Polymerase Kappa: Confirmatory Assay for Cherry-picked Compounds | 2012 | PloS one, , Volume: 7, Issue:10
| A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |